Biodexa Pharmaceuticals reschedules AGM to June 30 after quorum lapse
Biodexa Pharmaceuticals PLC adjourned its Annual General Meeting (AGM) on June 17, 2026, due to a lack of quorum. The meeting has been rescheduled for 11.00am BST on June 30, 2026, at the company's Cardiff offices. Proxies submitted for the original date remain valid for the new date.
*this image is generated using AI for illustrative purposes only.
Biodexa Pharmaceuticals PLC adjourned its Annual General Meeting (AGM) on June 17, 2026, due to a lack of quorum, preventing shareholders from voting on proposed resolutions. The clinical stage biopharmaceutical company, focused on gastrointestinal cancers, was unable to proceed with the meeting originally scheduled for 11.00am BST. Consequently, the company has rescheduled the AGM to ensure proper governance and shareholder participation.
In accordance with the Company's articles of association, the AGM cannot be reconvened for 10 clear days. The re-scheduled meeting will take place at 11.00am BST on June 30, 2026, at the Company's offices located at 1 Caspian Point, Caspian Way, Cardiff CF10 4DQ. This delay allows the company to regroup and ensure the necessary attendance requirements are met for the statutory proceedings.
Proxies submitted in time for the original AGM will remain valid for the re-scheduled AGM. This provision ensures that shareholders who had already appointed proxies do not need to resubmit their instructions, maintaining continuity in representation. The agenda for the meeting remains unchanged, addressing the matters originally set before the shareholders.
Meeting Details
| Detail | Information |
|---|---|
| Original Date | June 17, 2026 |
| Re-scheduled Date | June 30, 2026 |
| Time | 11.00am BST |
| Location | 1 Caspian Point, Caspian Way, Cardiff CF10 4DQ |
| Reason for Adjournment | Lack of quorum |
Biodexa Pharmaceuticals PLC is developing a pipeline of innovative products for the treatment of diseases with unmet medical needs. Its lead development programs include eRapa for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer, MTX240 for Gastrointestinal Stromal Tumors (GIST), and tolimidone for type 1 diabetes. The company's headquarters and R&D facility are located in Cardiff, UK.
What specific measures is Biodexa implementing to ensure sufficient shareholder attendance at the rescheduled AGM?
Could the inability to secure a quorum indicate underlying shareholder dissatisfaction with current management or strategic direction?
How might the delay in approving resolutions impact the timeline for key clinical milestones or funding decisions?
17
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
